As per DelveInsight, the Lupus Nephritis therapeutics market is anticipated to grow in the coming years owing to the increasing prevalent population of Lupus Nephritis in the 7MM and the launch of emerging therapies.
Talking about the emerging treatment horizon of Lupus Nephritis, several companies, including Roche, Novartis, AstraZeneca, and others, are eyeing the existing untapped market of Lupus Nephritis and trying their best to grab a significant market share. Some of the emerging therapies by these key players have already demonstrated positive late-stage results among Lupus Nephritis-affected individuals and are in further clinical evaluation.
“Lupus Nephritis Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Lupus Nephritis Market.
The Lupus Nephritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Lupus Nephritis Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for the treatment of Lupus Nephritis and the aggregate therapies developed by major pharma companies.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Lupus Nephritis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
DelveInsight’s Report covers around 20+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Lupus Nephritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Intravenous
Subcutaneous
Molecule Type
Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Small molecule
Mechanism of Action of the Emerging Pipeline Therapies
CD6 antigen inhibitors
Agammaglobulinaemia tyrosine kinase inhibitors
CD40 ligand inhibitors
Antibody-dependent cell cytotoxicity
Interleukin-23 subunit p19 inhibitors
LANCL2 agonist
Interferon alpha inhibitors
IL17A protein inhibitors
Extracellular trap inhibitors
Learn How the Ongoing Clinical & Commercial Activities will Affect the Lupus Nephritis Therapeutic Segment @
https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight
Lupus Nephritis Therapeutics Landscape
There are approx. 20+ key companies developing therapies for Lupus Nephritis. Currently, BeiGene is leading the therapeutics market with its Lupus Nephritis drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Lupus Nephritis Therapeutics Market Include:
Novartis Pharmaceuticals
Hoffmann-La Roche
Janssen Research & Development
BeiGene
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Alexion Pharmaceuticals
Omeros Corporation
Corestem, Inc.
Bristol-Myers Squibb
Boehringer Ingelheim
Apellis Pharmaceuticals
AstraZeneca
Kezar Life Sciences
Equillium
Eledon Pharmaceuticals
Resolve Therapeutics
And Many Others
Lupus Nephritis Drugs Covered in the Report Include:
Zanubrutinib: BeiGene
Ravulizumab: Alexion Pharmaceuticals
Anifrolumab: AstraZeneca
Itolizumab: Equillium
Secukinumab: Novartis Pharmaceuticals
NTR-441: Neutrolis Therapeutics
AT-1501: Eledon Pharmaceuticals
Obinutuzumab: Roche
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Lupus Nephritis Current Treatment Patterns
4. Lupus Nephritis – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Lupus Nephritis Late Stage Products (Phase-III)
7. Lupus Nephritis Mid-Stage Products (Phase-II)
8. Lupus Nephritis Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Lupus Nephritis Discontinued Products
13. Lupus Nephritis Product Profiles
14. Key Companies in the Lupus Nephritis Market
15. Key Products in the Lupus Nephritis Therapeutics Segment
16. Dormant and Discontinued Products
17. Lupus Nephritis Unmet Needs
18. Lupus Nephritis Future Perspectives
19. Lupus Nephritis Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
Other Trending Healthcare Reports By DelveInsight
Lupus Nephritis Market Outlook
“Lupus Nephritis Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Lupus Nephritis, historical and forecasted epidemiology as well as the Lupus Nephritis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2019 to 2032.
About DelveInsightDelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
